Steven Zelenkofske
Directeur/Membre du Conseil chez CADRENAL THERAPEUTICS, INC.
Fortune : 16 960 $ au 30/04/2024
Profil
Steven L.
Zelenkofske is currently the Director & Chief Strategy Officer at DiNAQOR AG and an Independent Director at Cadrenal Therapeutics, Inc. He is also an Associate Professor at Philadelphia College of Osteopathic Medicine and Hershey Medical Center.
In the past, Dr. Zelenkofske held positions such as Senior Director at Novartis Pharmaceuticals Corp., Clinical Director at The Heart Care Group, Chief Medical Officer & Executive Vice President at Achillion Pharmaceuticals, Inc., Chief Medical Officer at Regado Biosciences, Inc., Chief Patient Safety Officer at Cardiac Rhythm Management, VP-Cardiovascular & Thrombosis Medical Unit at Sanofi-Aventis Pharmaceuticals, Chief Medical Officer at uniQure NV, and Chief Medical Officer at SwanBio Therapeutics, Inc.Dr. Zelenkofske obtained his undergraduate and graduate degrees from Emory University and his doctorate from Philadelphia College of Osteopathic Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/03/2024 | 40 000 ( 0,25% ) | 16 960 $ | 30/04/2024 |
Postes actifs de Steven Zelenkofske
| Sociétés | Poste | Début |
|---|---|---|
| CADRENAL THERAPEUTICS, INC. | Directeur/Membre du Conseil | 19/01/2023 |
| Philadelphia College of Osteopathic Medicine | Corporate Officer/Principal | - |
| Hershey Medical Center | Corporate Officer/Principal | - |
DiNAQOR AG
 DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Directeur/Membre du Conseil | 01/05/2020 |
Anciens postes connus de Steven Zelenkofske
| Sociétés | Poste | Fin |
|---|---|---|
| ACHILLION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 28/01/2020 |
| UNIQURE N.V. | Directeur Technique/Scientifique/R&D | 01/09/2018 |
Regado Biosciences, Inc.
 Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Directeur Technique/Scientifique/R&D | 01/11/2014 |
| Sanofi-Aventis Pharmaceuticals | Corporate Officer/Principal | 01/01/2009 |
Cardiac Rhythm Management
 Cardiac Rhythm Management Medical SpecialtiesHealth Technology Part of Japan Lifeline Co., Ltd., Cardiac Rhythm Management is a company that manufactures implantable devices to treat arrhythmias. The company is based in Sylmar, CA. | Corporate Officer/Principal | - |
Formation de Steven Zelenkofske
| Emory University | Graduate Degree |
| Philadelphia College of Osteopathic Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| UNIQURE N.V. | Health Technology |
| CADRENAL THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Regado Biosciences, Inc.
Regado Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Regado Biosciences, Inc. is a biopharmaceutical company, which engages in the discovery and development of therapies in cardiovascular medicine using actively controlled aptamer technology. The company is focusing on new products for antithrombotic indications in the acute care and sub-acute care therapeutic setting. Its paired aptamer-active control agent technology is designed to give physicians the ability to directly control the degree of antithrombotic activity in real time on a "per patient, per setting" basis. The company's clinical programs are specifically concentrated on acute and sub-acute care injectable anticoagulants. Regado Biosciences was founded by Eli Gilboa, Bruce A. Sullenger and Christopher P. Rusconi on December 19, 2001 and is headquartered in Basking Ridge, NJ. | Health Technology |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Cardiac Rhythm Management
Cardiac Rhythm Management Medical SpecialtiesHealth Technology Part of Japan Lifeline Co., Ltd., Cardiac Rhythm Management is a company that manufactures implantable devices to treat arrhythmias. The company is based in Sylmar, CA. | Health Technology |
| Sanofi-Aventis Pharmaceuticals | |
The Heart Care Group
 The Heart Care Group Medical/Nursing ServicesHealth Services The Heart Care Group is an outpatient cardiac care practice that prioritizes wellbeing and preventative care. The American company offers a new take on cardiac wellness. | Health Services |
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
DiNAQOR AG
DiNAQOR AG BiotechnologyHealth Technology DiNAQOR AG is a Swiss genetic medicine platform company that focuses on developing innovative solutions for patients with severe, inherited forms of heart disease. The private company is based in Pfäffikon, Switzerland, and has additional presence in Massachusetts and other locations. The company's lead preclinical program, DINA-001, is aimed at treating mybpc3-linked cardiomyopathy. Founded in 2019, the CEO of DiNAQOR is Johannes Holzmeister. | Health Technology |
